On June 1, 2017, Genecast officially launched its new inspection product, Genecast PD-L1. Genecast is committed to not only precision diagnosis via tumor liquid biopsies, but also to immunohistochemical detection services that conform to trends in immunotherapy. 

Product introduction: Genecast PD-L1 detects PD-L1 and PD-1 proteins as well as mismatch repairs of solid tumors. Immunohistochemistry technology can assist tumor patients in selecting immune checkpoint inhibitors.